Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Adverse Event Reporting Reg Offers Few Exceptions

This article was originally published in The Pink Sheet Daily

Executive Summary

Companies must submit post-market safety reports electronically beginning in June 2015; waivers will be allowed, but they would only be temporary.

You may also be interested in...

FDA Adverse Event Electronic Reporting Delayed To Complete Portal Roll-Out

Because some submitters will not have enough time to register for new electronic submission system, FDA will continue accepting paper post-marketing safety reports a little longer.

Rx Regulatory Puzzle: FDA’s 2015 Agenda Comes Together Piece By Piece

Generic drug labeling, drug shortages and compounding will be tackled in regulations in 2015; three documents weave together a picture of FDA’s upcoming actions on pharmaceutical-related rules.

Vaccine Electronic Safety Reporting Guidelines Follow Drug Model

FDA draft guidance explains procedures sponsors should use for electronic submissions to the Vaccine Adverse Event Reporting System when new requirements take effect in June 2015.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts